Navigation Links
The Central Government of India had issued a list of approved ingredients for use in ayurvedic, siddha, unani drugs

The Central Government of India has now issued a list of permitted additives ,preservatives// and antioxidants with their corresponding reference standards or grades that should be followed in the manufacture of Ayurveda, Siddha or Unani drugs. The list was issued after a number of reports claimed that individuals found consuming such medications on a long-term basis had developed adverse effects.

The substances permitted according to the list consists of 87 additives, 14 preservatives and six antioxidants. In the case of colouring agents, flavouring agents and alternate sweeteners, it has been mentioned that the permission would be on the basis of the existing approvals accorded under Drugs and Cosmetic Rules 1945, Fruits Products Order and Prevention of Food Adulteration Act. According to the notice issued preservatives, alternative sweeteners and colouring agents that are used should be mentioned on the label of the product and manufacturing units should maintain the records of additives used in various processes and dosage preparation.
'"/>




Page: 1

Related medicine news :

1. Centralization of Hospital Services Inconveniencing Patients
2. Poor Health Care in Rural Australia,Central Funding Required: Vaile
3. Poor Health of people in Central Goldfields Shire, reports The Victorian Burden of Disease
4. Venugopal will not be Sacked Before Court Verdict: Central Government
5. Central Government to Caution all States About Soft Drinks
6. Central Budget Allocates Rs.99.47 Bn Proposal for Rural Health Mission
7. Bird Flu Outbreak in Chonan, Central South Korea
8. The Indian Government has given the nod to conduct Human volunteer trials inorder to develop preventive AIDS vaccines
9. Tanzanian Government Sanctions $20 Million For AIDS Arug
10. Government Organisation Proposes Strict Guidelines For SubStandard Medical Devices
11. Indian Government warns Gujarat regarding possibility of bird flu
Post Your Comments:
(Date:12/4/2008)...TIST HEALTH, a six-hospital,system based in Littl...m, has,expanded its use of Clinical Xpert(TM) Car...abled the system,s pharmacists to increase necessa...illion. , "Data we collected for the 220-be...ompts approximately half of the pharmacy clinical ...
(Date:12/4/2008)...study of 491 women with invasive ovarian cancer fo...r genetic testing of BRCA1 and BRCA2, the breast c...formed of their cancer risk. , Dr. Kelly Metcal...ronto,s Lawrence S. Bloomberg Faculty of Nursing, ...ch Institute, led the nursing study, which was pub...
(Date:12/4/2008)... on the eve of its 35th Anniversary, Ronald McDona...d Season of Giving marketing campaign to remind co...itiative, designed to drive personal donations, wi...ree core programs: Ronald McDonald House, Ronald M...obile. , OAK BROOK, III....
(Date:12/4/2008)...en Joffe, Craig Joffe, and,Alan Buckey today file...,Securities and Exchange Commission. The group p...4% of LCA-Vision, Inc. (Nasdaq: LCAV ), which,o...ction centers in 33 states,in the United States. ...CEO of,LCAV. Craig Joffe is the former Chief Ope...
Breaking Medicine News(10 mins):Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 3Health News:Few Ontario women with invasive ovarian cancer referred for genetic testing of breast cancer genes 2Health News: Ronald McDonald House Charities Brings People Together Like Never Before with First-Ever, Multi-Channel Social Networking Campaign : Charity Finds New Ways to Encourage Seasonal Giving in Tough Economic Times 2Health News: Ronald McDonald House Charities Brings People Together Like Never Before with First-Ever, Multi-Channel Social Networking Campaign : Charity Finds New Ways to Encourage Seasonal Giving in Tough Economic Times 3Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 2Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 3Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 4Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 5Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 6
...l infections with an antibiotic gel reduced the pr...oughout the body,// pointing to further evidence o...ealth, investigators from the University at Buffal.... The investigators divided a sample of 100 adult...
...diation may cause skin cancer, but it also prevent... According to many, UV-B - the solar radiation tha..., and other skin cancers. That is generally true, ...that the reverse may also be the case - that UV-B ...
...icals Ltd today said its newly- found andti-diabet... trials by later this year. Mr Glenn Saldanha, Exe...wspersons that the company’s R&D team has establis... this molecule.// The global diabetes market is e...
...f bypass patients suffer mental decline after bypa...mbering. One leading theory is that the heart-lung...udy,// the loss of mental sharpness suffered by ma...gery may not be caused by the heart-lung machine u...
Other Medicine News:
(Date:12/3/2008)...3 Wyeth Pharmaceuticals,...day that it has submitted a,marketing authorizati...ncy,(EMEA) for approval to market its investigati...V13) for infants and young children. Wyeth is see...ccal disease (PD) caused by the 13,serotypes incl...
(Date:12/2/2008)...ire-USNewswire/ -- Researchers using functional,M...e area of the brain,responsible for suppressing m...,stress-related psychiatric disorders. Results of ...eeting of the Radiological Society of North Americ...ssion and other stress-related disorders,traumat...
(Date:12/2/2008)...Newswire/ -- Horizon Therapeutics, Inc., a,privat...d that two pivotal,Phase 3 trials evaluating its ...met all primary endpoints. HZT-501, a novel, propr...ibuprofen and famotidine, demonstrated a,statisti...n-steroidal,anti-inflammatory drug (NSAID)-induce...
(Date:12/1/2008)...swire/ -- TargeGen has announced that an oral,pre...ter, US-based clinical,trial of TG101348 in myelo...at,the 2008 American Society of Hematology (ASH) ...e as follows:, Title: A Phase I... JAK2-Selective Inhibitor, in Pat...
Breaking Medicine Technology:Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Plexus Systems Inc and Aberdeen Group Co host March 27 Webinar on Manufacturing Efficiency 15096 1Plexus Systems Inc and Aberdeen Group Co host March 27 Webinar on Manufacturing Efficiency 15096 2Plexus Systems Inc and Aberdeen Group Co host March 27 Webinar on Manufacturing Efficiency 15096 3MRI Can Be Predictor of Post Treatment Prostate Cancer Spread 15095 1MRI Can Be Predictor of Post Treatment Prostate Cancer Spread 15095 2Mounting evidence shows red wine antioxidant kills cancer 2618 1Mounting evidence shows red wine antioxidant kills cancer 2618 2Mounting evidence shows red wine antioxidant kills cancer 2618 3New York City Staffing Company Charged With Violating H 1B Program Following U S Labor Department Finding Almost 243 Million in Back Wages Due 156 W 15090 1New York City Staffing Company Charged With Violating H 1B Program Following U S Labor Department Finding Almost 243 Million in Back Wages Due 156 W 15090 2
...ne Plus Minocycline Showed Substantial,Reduction o...ng-Remitting Multiple Sclerosis , Combination Trea...s and Was Well Tolerated , KANSAS CITY, Mo, May 4,...tudy showed that a combination of Copaxone,(glatir...otic,minocycline reduced T1 Gadolinium (Gd)-enhanc...
...th May 2007 - CeNeS Pharmaceuticals plc,(LSE: CEN)...otes,the publication of an independent study in th...hase II NMDA antagonist, CNS 5161. CeNeS,is develo...thic,pain. The independent study builds on the wor... , In the study reported in ,Synapse, Dr Anat Bie...
Other Medicine Technology:Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 6Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 7Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 8Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 10Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 11Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 12Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3
Large solid mallet with patented Ortho-Grip® silicone rubber handle.
Angled ring curette.
Perisoteal rasp for elevating, dissecting, and scraping.
Stainless steel bone clamp.
Medicine Products: